Dow Down1.40% Nasdaq Down1.59%

MediciNova Inc. (MNOV)

3.13 Up 0.14(4.68%) Oct 1, 4:00PM EDT
ProfileGet Profile for:
MediciNova Inc.
4275 Executive Square
Suite 650
La Jolla, CA 92037
United States - Map
Phone: 858-373-1500
Fax: 858-404-0048

Index Membership:N/A
Full Time Employees:11

Business Summary 

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a ß2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on MediciNova Inc.

Key Executives 
Dr. Yuichi Iwaki M.D., Ph.D., 64
Co-Founder, Chief Exec. Officer, Pres and Exec. Director
Mr. Masatsune Okajima , 46
Head of Japanese Office and VP
Dr. Kazuko Matsuda M.D., Ph.D., MPH, 48
Chief Medical Officer
Ms. Esther van den Boom ,
Chief Financial Officer
Dr. Joji Suzuki M.D., Ph.D., 52
Sr. VP of Fin. & Admin.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders